Bladder Cancer Special Session EAU 2019 VL

Blue Light Cystoscopy with CYSVIEW: Improving Detection Rates of Bladder Cancer in the Clinic - Yair Lotan

Details
Yair Lotan discusses the advancements in the ability to detect bladder cancer and bladder cancer recurrence in the clinic with blue light cystoscopy. Until recently, the technology was only available in the OR but now, with the approval of blue light flexible cystoscopy bladder cancer surveillance can now be done in the clinic. The blue light cystoscopy with CYSVIEW is performed in the clinic to d...

Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner

Details
Seth Lerner discusses the evidence supporting the integrated treatment approaches to advanced bladder cancer that begins with neoadjuvant chemotherapy (cisplatin-based therapy) followed by cystectomy demonstrates clinical response for patients with Ashish Kamat. Advances in chemotherapy for metastatic disease have prompted trials of systemic therapy in patients with early stage, high-risk disease...

Treating Advanced Bladder Cancer - Petros Grivas

Details
Petros Grivas, MD Ph.D. and Alicia Morgans discuss the rapidly changing landscape in the treatment of advanced urothelial cancer. Dr. Grivas discusses the era of immunotherapy in advanced bladder cancer and the development of new drugs, new combinations, and biomarkers. Biographies: Petros Grivas, MD, Ph.D. is an Associate Professor and the Clinical Director of the Genitourinary Cancers Program at...

Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf

Details
Wassim Kassouf and Alicia Morgans discuss the role of neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) including the accuracy of clinical staging and treatments. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a Professor in the Division of Urology and Vice-Chair of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and ren...

Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou

Details
Despite the fact that most patients do well with a radical cystectomy, the procedure is physiologically challenging and is associated with real morbidity, including hospitalizations, risk of re-operation, long-term sequelae and post-operative mortality. Jason Efstathiou, MD discusses the progress in trimodality therapy with the combination of surgery, chemotherapy, and radiation. Trimodality thera...

Challenges in the Diagnosis and Treatment of UTUC - Peter Black

Details
Peter Black, MD discusses the challenges in both the diagnosis and treatment of UTUC. First, Dr. Black mentions the difficulty in obtaining adequate tissue for confirmation of diagnosis and to risk stratify patients. Traditionally diagnosis has been made based on imaging alone due to the challenges with obtaining biopsies leading to overtreatment for many patients. Due to the inability to appropri...

The EAU Committed to Educating Urologists Around the Globe - Juan Palou

Details
Charles Ryan, MD, and Juan Palou, MD, Ph.D., FEBU discuss the role of the EAU (European Association of Urology) in driving urology education around the globe. At the 2019 EAU meeting, they offered 54 teaching courses, that are attended by one-third of the people attending the meeting. So that means there are three or four thousand urologists attending each of the offered courses. Training is a foc...

Optimal Surgical Approaches in Cystectomy - Piyush Agarwal

Details
Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan. If you look at the robotic literature in urologic cancers, there is no evidence of any o...

Overview of the Special Bladder Cancer Session - Ashish Kamat

Details
Ashish Kamat, MD discusses the special bladder cancer session that he and Arnulf Stenzel developed and facilitated at the EAU in 2019. This is the second year that Dr. Kamat has hosted this session which was a 3-hour session of relevant clinical topics in the field and expert debates. Experts from all over the world came together to debate important topics including IO as adjuvant therapy and the...

Improving Outcomes in Bladder Cancer - Arnulf Stenzl

Details
Arnulf Stenzl is the co-facilitator of the case-based specialty session. Here he discusses improving outcomes in non-muscle invasive bladder cancer with the en bloc resection for cancers that are smaller than one centimeter which is consistent with the EAU guidelines. Dr. Stenzl has been performing en bloc resections for tumors up to 3 centimeters which provides more information on staging. He als...